Breakthrough Study Published in Blood: Nanobody-Based CD7 CAR-T Therapy for Acute Myeloid Leukemia
The Lu Daopei Medical Team has made a remarkable stride in the field of hematology. Under the leadership of Dr. Lu Peihua, their groundbreaking study, “Nanobody-based Naturally Selected CD7-Targeted Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia”, was recently published in the internationally renowned journal Blood (Impact Factor: 21). This research highlights a revolutionary approach to treating acute myeloid leukemia (AML), showcasing exceptional tumor-killing efficacy and safety while providing new hope for patients with relapsed or refractory (R/R) AML.
Innovative Approach
The study pioneers the use of nanobody-based CD7 CAR-T cells in AML therapy. Traditional CAR-T therapies typically employ single-chain variable fragments (scFv) derived from monoclonal antibodies (mAbs). This research leveraged nanobodies—single-domain antibodies derived from camelid heavy-chain antibodies. Nanobodies, due to their smaller size (15kDa compared to the 150kDa human IgG) and reduced immunogenicity, provide superior antigen specificity and binding affinity while minimizing side effects.
The nanobody-based NS7CAR-T demonstrated enhanced anti-tumor efficacy and safety in both preclinical and clinical trials. Preclinical results revealed superior cell proliferation and antitumor activity compared to scFv-based CAR-T cells. Moreover, in a Phase I clinical trial, the treatment achieved a 70% complete remission rate among 10 CD7-positive AML patients, with 60% attaining minimal residual disease (MRD)-negative status.
Clinical Impact
The trial enrolled patients with high-risk profiles, including those with prior hematopoietic stem cell transplants (allo-HSCT) or multiple lines of therapy. Despite these challenges, the nanobody-based NS7CAR-T therapy achieved promising outcomes with manageable side effects, including mild cytokine release syndrome (CRS) in 80% of participants. No cases of neurotoxicity were observed.
Future Directions
The study underscores the need for larger trials to further validate the efficacy and safety of nanobody-based CD7 CAR-T therapy in AML treatment. It also highlights challenges such as CD7 antigen loss, which remains a significant hurdle in relapsed cases. Addressing these issues will be key to optimizing the therapy for broader clinical applications.
A New Horizon for AML Treatment
AML, a highly complex and heterogeneous hematologic malignancy, has long posed challenges in achieving durable remission and improving overall survival rates. The innovation introduced by the Lu Daopei Medical Team not only offers a new therapeutic avenue for patients but also reinforces their academic prominence in global hematology research.
This milestone serves as a testament to the team's dedication to bridging cutting-edge research and clinical practice. As the team continues to explore groundbreaking treatments, their work brings renewed hope to patients worldwide and paves the way for transformative advancements in hematology.